Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. (2015)
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1016/s0140-6736(15)00257-3
PubMed Identifier: 26414968
Publication URI: http://europepmc.org/abstract/MED/26414968
Type: Journal Article/Review
Volume: 386
Parent Publication: Lancet (London, England)
Issue: 10008
ISSN: 0140-6736